Michael Ulz

Stock Analyst at Baird

(4.04)

# 472

Out of 4,851 analysts

115

Total ratings

50%

Success rate

12.78%

Average return

Main Sectors:

Top Industries:

Stocks Rated by Michael Ulz

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	KPTI Karyopharm Therapeutics	Maintains: Outperform	$54 → $42	$4.25	+888.24%	6	May 13, 2025
	SLN Silence Therapeutics	Maintains: Overweight	$45 → $25	$5.41	+362.11%	12	May 9, 2025
	VKTX Viking Therapeutics	Maintains: Overweight	$105 → $102	$26.61	+283.31%	3	Apr 24, 2025
	ALNY Alnylam Pharmaceuticals	Maintains: Equal-Weight	$284 → $268	$303.77	-11.78%	10	Apr 11, 2025
	KYTX Kyverna Therapeutics	Maintains: Overweight	$40 → $20	$2.79	+616.85%	2	Apr 1, 2025
	CABA Cabaletta Bio	Maintains: Overweight	$30 → $22	$2.18	+909.17%	6	Apr 1, 2025
	AARD Aardvark Therapeutics	Initiates: Overweight	$29	$11.66	+148.71%	1	Mar 10, 2025
	YMAB Y-mAbs Therapeutics	Maintains: Underweight	$11 → $7	$4.88	+43.44%	7	Mar 5, 2025
	IOVA Iovance Biotherapeutics	Maintains: Outperform	$24 → $20	$1.82	+998.90%	4	Feb 28, 2025
	THRD Third Harmonic Bio	Downgrades: Equal-Weight	$20 → $5	$5.25	-4.76%	5	Feb 12, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$18 → $10	$1.95	+412.82%	2	Feb 3, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$46 → $96	$51.68	+85.76%	4	Jan 28, 2025
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$48 → $52	$13.27	+291.86%	2	Aug 14, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Equal-Weight	$110 → $115	$127.60	-9.87%	9	Jul 12, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$53 → $57	$45.29	+25.86%	3	Jun 18, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Equal-Weight	$36 → $27	$16.61	+62.55%	4	May 13, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Equal-Weight	$3 → $7	$1.36	+414.71%	8	Feb 27, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Equal-Weight	$45 → $48	$34.76	+38.09%	4	Nov 3, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Outperform	$15 → $27	$8.40	+221.43%	2	Aug 16, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Equal-Weight	$30 → $20	$3.15	+534.92%	3	Mar 24, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Initiates: Overweight	$45	$2.96	+1,420.27%	1	Feb 1, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$20 → $10	$0.68	+1,379.51%	3	Jan 27, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Downgrades: Equal-Weight	$3	$2.78	+7.91%	1	Jan 27, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Upgrades: Equal-Weight	$18 → $30	$5.23	+473.61%	1	Jan 27, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Equal-Weight	$25 → $30	$1.25	+2,309.64%	3	Mar 30, 2022
	XXXX XXXXXXXXXXXXXXXX Upgrade	Initiates: Outperform	$45	$10.11	+345.32%	1	Oct 8, 2020
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Outperform	$12 → $20	$0.35	+5,633.94%	2	May 28, 2020
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Outperform	$85 → $80	$36.40	+119.78%	3	Nov 3, 2017
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Outperform	$12 → $15	$6.27	+139.43%	3	Jul 12, 2017

Karyopharm Therapeutics

May 13, 2025

Maintains: Outperform

Price Target: $54 → $42

Current: $4.25

Upside: +888.24%

Silence Therapeutics

May 9, 2025

Maintains: Overweight

Price Target: $45 → $25

Current: $5.41

Upside: +362.11%

Viking Therapeutics

Apr 24, 2025

Maintains: Overweight

Price Target: $105 → $102

Current: $26.61

Upside: +283.31%

Alnylam Pharmaceuticals

Apr 11, 2025

Maintains: Equal-Weight

Price Target: $284 → $268

Current: $303.77

Upside: -11.78%

Kyverna Therapeutics

Apr 1, 2025

Maintains: Overweight

Price Target: $40 → $20

Current: $2.79

Upside: +616.85%

Cabaletta Bio

Apr 1, 2025

Maintains: Overweight

Price Target: $30 → $22

Current: $2.18

Upside: +909.17%

Aardvark Therapeutics

Mar 10, 2025

Initiates: Overweight

Price Target: $29

Current: $11.66

Upside: +148.71%

Y-mAbs Therapeutics

Mar 5, 2025

Maintains: Underweight

Price Target: $11 → $7

Current: $4.88

Upside: +43.44%

Iovance Biotherapeutics

Feb 28, 2025

Maintains: Outperform

Price Target: $24 → $20

Current: $1.82

Upside: +998.90%

Third Harmonic Bio

Feb 12, 2025

Downgrades: Equal-Weight

Price Target: $20 → $5

Current: $5.25

Upside: -4.76%

Feb 3, 2025

Maintains: Overweight

Price Target: $18 → $10

Current: $1.95

Upside: +412.82%

Jan 28, 2025

Maintains: Overweight

Price Target: $46 → $96

Current: $51.68

Upside: +85.76%

Aug 14, 2024

Maintains: Overweight

Price Target: $48 → $52

Current: $13.27

Upside: +291.86%

Jul 12, 2024

Maintains: Equal-Weight

Price Target: $110 → $115

Current: $127.60

Upside: -9.87%

Jun 18, 2024

Maintains: Overweight

Price Target: $53 → $57

Current: $45.29

Upside: +25.86%

May 13, 2024

Maintains: Equal-Weight

Price Target: $36 → $27

Current: $16.61

Upside: +62.55%

Feb 27, 2024

Maintains: Equal-Weight

Price Target: $3 → $7

Current: $1.36

Upside: +414.71%

Nov 3, 2023

Maintains: Equal-Weight

Price Target: $45 → $48

Current: $34.76

Upside: +38.09%

Aug 16, 2023

Maintains: Outperform

Price Target: $15 → $27

Current: $8.40

Upside: +221.43%

Mar 24, 2023

Maintains: Equal-Weight

Price Target: $30 → $20

Current: $3.15

Upside: +534.92%

Feb 1, 2023

Initiates: Overweight

Price Target: $45

Current: $2.96

Upside: +1,420.27%

Jan 27, 2023

Maintains: Overweight

Price Target: $20 → $10

Current: $0.68

Upside: +1,379.51%

Jan 27, 2023

Downgrades: Equal-Weight

Price Target: $3

Current: $2.78

Upside: +7.91%

Jan 27, 2023

Upgrades: Equal-Weight

Price Target: $18 → $30

Current: $5.23

Upside: +473.61%

Mar 30, 2022

Maintains: Equal-Weight

Price Target: $25 → $30

Current: $1.25

Upside: +2,309.64%

Oct 8, 2020

Initiates: Outperform

Price Target: $45

Current: $10.11

Upside: +345.32%

May 28, 2020

Maintains: Outperform

Price Target: $12 → $20

Current: $0.35

Upside: +5,633.94%

Nov 3, 2017

Maintains: Outperform

Price Target: $85 → $80

Current: $36.40

Upside: +119.78%

Jul 12, 2017

Maintains: Outperform

Price Target: $12 → $15

Current: $6.27

Upside: +139.43%